PGE2 Binding Antibodies for Selective Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for managing excess production of prostaglandin E2 (PGE2) in diseases such as rheumatoid arthritis and inflammation lack specificity, leading to adverse effects due to non-selective inhibition of COX-1 and COX-2 pathways, which affect cardiovascular homeostasis and gastric protection.
Innovation Solution
Development of specific binding proteins, including antibodies and antigen binding fragments, that selectively bind to PGE2, preventing its interaction with PGE2 receptors (EP1, EP2, EP3, and EP4) to modulate its biological functions, thereby reducing inflammation and pain without affecting other prostaglandins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective COX-1 and COX-2 inhibition is used to reduce PGE2 production, then inflammation and pain are reduced, but adverse effects occur on cardiovascular homeostasis and gastric protection
Solution Approach 1:
The patent uses monoclonal antibodies (e.g., 2B5, 4F10, 15F10) as intermediary substances that specifically bind to PGE2, preventing it from interacting with its receptors. This intermediary approach allows selective neutralization of PGE2 without affecting other prostaglandins that maintain cardiovascular homeostasis and gastric protection, thus resolving the contradiction between anti-inflammatory efficacy and adverse effects
Solution Approach 2:
The invention applies the principle of local quality by creating antibodies with specific binding characteristics tailored to PGE2. The antibodies possess unique paratope structures that recognize and bind only to PGE2's specific epitopes, allowing localized and selective neutralization of PGE2's harmful effects while leaving other physiological processes intact
2Measurement precision
If specific binding proteins are developed to selectively bind PGE2, then specificity and affinity for PGE2 are improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent employs self-service principles in antibody generation through hybridoma technology, where immunized cells automatically produce and secrete the desired monoclonal antibodies. The system self-organizes to produce consistent, high-affinity antibodies without requiring complex external intervention for each antibody generation process
Solution Approach 2:
The invention applies preliminary action by pre-screening and characterizing antibody candidates using established assays (ELISA, radioimmunoassay, competitive binding assays) before selecting the optimal antibodies for further development. This preliminary characterization streamlines the selection process and reduces overall complexity by identifying suitable candidates early
Data Source
AI summary
The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.